Three‐Year Long‐Term Outcomes in Patients With Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab Treatment in Clinical Practice

TL;DR

This study reports on the long-term outcomes of patients with unresectable liver cancer treated with a combination of two drugs, showing a 30% survival rate after three years.

Contribution

The study provides real-world clinical data on 3-year survival rates for unresectable hepatocellular carcinoma patients treated with atezolizumab and bevacizumab.

Findings

The 3-year survival rate was 29.7% in patients treated with atezolizumab plus bevacizumab.

First-line therapy users had a higher 3-year survival rate of 35.9%.

Post-progression survival was 10.9 months for patients who received further treatment after disease progression.

Abstract

Findings regarding long‐term outcomes of unresectable hepatocellular carcinoma (uHCC) patients treated with atezolizumab and bevacizumab (Atez/Bev) have yet to be reported. This study was performed to evaluate results regarding 3 year survival of such patients treated in real‐world clinical settings.

This multicenter retrospective study included 555 patients with Child‐Pugh A and BCLC stage B or C, for whom Atez/Bev treatment was initiated in the period from 2020 to 2021. Best treatment response, progression‐free survival (PFS), overall survival (OS), post‐progression survival (PPS), and immune‐related adverse events (irAEs) were analyzed.

Median age was 73 years and 80.2% were male. Atez/Bev was given as first‐line therapy in 55.3%. Objective response rate (ORR) was 41.3% and disease control rate (DCR) was 79.4%. Median PFS was 6.2 months, while median OS was 21.6 months with a 3 year survival rate of 29.7%. Patients treated with Atez/Bev as first‐line therapy showed a higher 3 year survival rate of 35.9%. Post‐progression treatment was administered to 54.1% of the patients and median PPS in those was 10.9 months. Conversion therapy was performed in 5.9%. IrAEs occurred in 13.3% (grade 5: 0.7%).

uHCC patients treated with Atez/Bev in clinical practice settings showed good ORR and DCR, as well as favorable long‐term survival with a 3 year survival rate of approximately 30%, including 35.9% for first‐line users.

Figures